Management of hepatitis C

British Medical Bulletin

Volumn 70, Issue , 2004, Pages 51-69

  Teo, Marcus ^a,b   Hayes, Peter ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b NONE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIDEPRESSANT AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; VIRUS ANTIBODY; VIRUS RNA;

ANEMIA; ANOREXIA; AUTOIMMUNE DISEASE; CHRONIC LIVER DISEASE; CLINICAL TRIAL; CONCENTRATION LOSS; DEPRESSION; DIAGNOSTIC ACCURACY; DIARRHEA; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HAIR LOSS; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INJECTION SITE REACTION; INSOMNIA; LEUKOPENIA; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MENTAL DISEASE; MYALGIA; NAUSEA; NEUTROPENIA; PHARYNGITIS; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RASH; REVIEW; RIGOR; RNA ANALYSIS; SUPERINFECTION; TERATOGENICITY; THROMBOCYTOPENIA; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOTHERAPY; INTERFERONS; LIVER CIRRHOSIS; LIVER NEOPLASMS; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 11244327853     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/bmb/ldh022     Document Type: Review

References (63)

1. Lauer G, Walker BD (2001) Hepatitis C virus infection. N Engl J Med, 345, 41-52.
2. Poynard T, Yeun M-F, Ratziu V, Lai CL (2003) Viral hepatitis C. Lancet, 362, 2095-2100.
3. Saab S, Wang V (2003) Recurrent hepatitis C following liver transplant: diagnosis, natural history and therapuetic options. J Clin Gastroenterol, 37, 155-163.
4. Adam R, McMaster P, O'Grady JG et al. (2003) Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl, 9, 1231-1243.
5. Alberti A, Benuvegnu L (2003) Management of hepatitis C. J Hepatol, 38, S104-S118.
6. Seeff LB (2002) Natural history of chronic hepatitis C. Hepatology, 36, S35-S46.
7. Kenny-Walsh E (1999) Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med, 340, 1228-1233.
8. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U (2000) Low frequency of cirrhosis in a hepatitis C (genotype 1b) single source outbreak in Germany, a 20 year multicenter study. Hepatology, 32, 91-96.
9. Poynard T, Bedossa P, Opolol P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet, 349, 825-832.
10. Liu C-J, Ali M-Y, Kao J-H, Shen D-S (2003) Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology, 37, 568-576.
11. Bellentani S, Pozzato G, Saccoccio G et al. (1999) Clinical course and risk factors of hepatitis C virus related liver disease in the general population, report from the Dionysos study. Gut, 44, 874-880.
12. Mayo MJ (2002) Southwestern Internal Medicine Conference: extrahepatic manifestations of hepatitis C. Am J Med Sci, 325, 135-148.
13. Pawlotsky J-M (2002) Use and interpretation of virologic tests for hepatitis C. Hepatology, 36, S65-S73.
14. McHutchison JG, Gordon SC, Schiff ER et al. (1998) Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med, 339, 1485-1492.
15. Poynard T, Marcellin P, Lee S, et al. (1998) Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitic C virus. Lancet, 352, 1426-1432.
16. Poynard T, McHutchison J, Goodman Z et al. (2000) Is an 'à la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology, 31, 211-218.
17. Fried MW, Shiffman ML, Redd, R et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med, 347, 975-982.
18. Manns MP, McHutchison JG, Gordon SC et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa 2b plus ribavirin for the initial treatment of chronic hepatitis C, a randomised trial. Lancet, 358, 958-965.
19. Hadziyannis SJ, Sette H, Morgan TR et al. (2004) Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med, 140, 346-355.
20. Pawlotsky J-M, Bouvier-Alias M, Hezade C, Darthuy F, Remire J, Dhumeaux D (2000) Standardization of hepatitis C virus RNA quantification. Hepatology, 32, 654-659.
21. Lindsay KL (2002) Introduction to therapy of hepatitis C. Hepatology, 36, S114-S120.
22. Hoofnagle JH (2002) Course and outcome of hepatitis C. Hepatology, 36, S21-S29.
23. Khan MH, Farrell GC, Byth K et al. (2000) Which patients with hepatitis C develop liver complications. Hepatology, 31, 513-520.
24. Zeuman S, Feinman V, Rasenack J et al. (2000) Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med, 343, 1666-1672.
25. Heathcote EJ, Shiffman ML, Cooksley WGE et al. (2000) Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med, 343, 1673-1680.
26. Davis GL (2002) Monitoring of viral levels during therapy of hepatitis C. Hepatology, 36, S145-S151.
27. Poynard T, McHutchison J, Manns M et al. (2002) Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology, 122, 1303-1313.
28. Yoshida H, Shiraori Y, Moriyama M et al. (1999) Interferon therapy reduces the risk for hepatocellular carcinoma, national surveillance program of cirrhotic and non cirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med, 131, 174-181.
29. Camm A, Giunta M, Andreone P, Craxi A (2001) Interferon and prevention of hepatocellular carcinoma in viral cirrhosis, an evidence based approach. J Hepatol, 34, 593-602.
30. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ (2001) Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis, a meta-analysis. Aliment Pharmacol Ther, 15, 689-698.
31. Imazeki F, Yokosuka O, Fukai K, Saisho H (2003) Favourable prognosis of chronic hepatitis C after interferon therapy by longterm cohort study. Hepatology, 38, 493-502.
32. Yoshida H, Arakawa Y, Sata M et al. (2002) Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology, 123, 483-491.
33. Esteban R (2003) Can interferon prolong life? Hepatology, 38, 292-294.
34. Fried MW (2002) Side effects of therapy of hepatitis C and their management. Hepatology, 36, S237-S244.
35. Koukoulis GK (2001) Chronic hepatitis C: grading, staging, and searching for reliable predictors of outcome. Hum Pathol, 32, 899-903.
36. Dienstag JL (2002) The role of liver biopsy in chronic hepatitis C. Hepatology, 36, S152-S160.
37. Yano M, Kumada H, Kage M et al. (1996) The long term pathological evolution of chronic hepatitis C. Hepatology 1996, 23, 1334-1340.
38. Fontane H, Nalpas B, Poulet B et al. (2001) Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol, 32, 904-909.
39. National Institute of Health (2002) National Institute of Health Consensus Development Conference Statement. Management of hepatitis. Hepatology, 36, S3-S20.
40. National Institute for Clinical Excellence (NHS) (2004) Interferon alfa (pegylated) and non-pegylated) and ribavirin for the treatment of chronic hepatitis C. Technology Appraisal 75. London: NICE. Available on-line at www.nice.org.uk
41. Ryder SD (2004) Progression of hepatic fibrosis in patients with hepatitis C, a prospective repeat liver biopsy study. Gut, 53, 451-455.
42. Royal College of Physicians (2004) Royal College of Physicians HCV Consensus Conference. J Viral Hepat, in press.
43. Bacon BR (2002) Treatment of patients with Hepatitis C and normal serum aminotransferase. Hepatology, 36, S179-S184.
44. Puoti C, Castellacci R, Montagnese F et al. (2002) Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian Prospective Study of The Asymptomatic Carriers (ISACC). J Hepatol, 37, 117-123.
45. Persico M, Persico E, Suozzo R et al. (2000) Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology, 118, 760-764.
46. Hui CK, Monto A, Belaye T, Lau E, Wright TL (2003) Outcomes of interferon alfa and ribavirin treatment for chronic hepatitis C in patients with normal serum transaminases. Gut, 52, 1644-1648.
47. Shiffman ML (2002) Retreatment of patients with chronic hepatitis C. Hepatology, 36, S128-S134.
48. Shiffman ML, Di Bisceglie AM, Lindsay KL et al. (2004) Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology, 126, 1015-1024.
49. Wright TL (2002) Treatment of patients with hepatitis C and cirrhosis. Hepatology, 36, S185-S194.
50. Strader D, Wright T, Thomas DL, Seeff LB (2004) Diagnosis, management and treatment of hepatitis C. Hepatology, 39, 1147-1171.
51. Everson GT (2004) Treatment of chronic hepatitis C in patients with decompensated cirrhosis. Rev Gastroenterol Disord, 4 (Suppl 1), S31-S38.
52. Wiesner RH, Sorrell M, Villamil F, and the International Liver Transplantation Society Expert Panel (2003) Report of the First International Liver Transplantation Society Expert Panel Consensus Conference on Liver Transplantation and Hepatitis C. Liver Transpl, 9 (Suppl 3), S1-S9.
53. Shiffman ML, Vargas HE, Everson GT (2003) Controversies in the management of hepatitis C virus infection after liver transplantation. Liver Transpl, 9, 1129-1144.
54. Thomas DL (2002) Hepatitis C and human immunodeficiency virus infection. Hepatology, 36, S201-S209.
55. Brau N, Rodriguez-Torres M, Prokupek D et al. Treatment of chronic hepatitis C in HIV/HCV coinfected with interferon alfa-2b+ Full course vs. 16 week delayed ribavirin. Hepatology, 39, 989-998.
56. Alberti A, Boccato S, Vario A, Benvegnu L (2002) Therapy of acute hepatitis C. Hepatology, 36, S195-S200.
57. Jaekel E, Cornberg M, Wedemeyer H et al. (2001) Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med, 345, 1452-1457.
58. Gerlach JT, Diepolder HM, Zachoval R et al. (2003) Acute hepatitis C: high rate of spontaneous and treatment-induced viral clearance. Gastroenterology, 125, 80-88.
59. Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology, 36, S220-S225.
60. Terrault NA (2002) Sexual activity as a risk factor for hepatitis C. Hepatology, 36, S99-S105.
61. Gebo KA, Chander G, Jencked MW et al. (2002) Screening test for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology, 36, S84-S92.
62. Llovet J, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet, 362, 1907-1917.
63. Sangiovanni A, Del Ninio E, Fasani P et al. (2004) Increased survival of cirrhotic patients with hepatocellular carcinoma detected during surveillance. Gastroenterology, 126, 1005-1014.